Gastroenterology Research, ISSN 1918-2805 print, 1918-2813 online, Open Access
Article copyright, the authors; Journal compilation copyright, Gastroenterol Res and Elmer Press Inc
Journal website http://www.gastrores.org

Review Article

Volume 4, Number 4, August 2011, pages 162-167

Biotherapy in the Adjuvant Treatment of Colorectal Cancer

Tables

Table 1. Differences Between the NASBP C-08 and AVANT Trials
 
VariableNASBP C-08AVANT
Abbreviations: FOLFOX = infusional 5-fluorouracil/leucovorin/oxaliplatin; NSABP = National Surgical Adjuvant Breast and Bowel Project; XELOX = capecitabine/oxaliplatin.
Number of arms23
Chemotherapy regimenmFOLFOX 6FOLFOX 4, XELOX
Maintenance Bevacizumab5 mg/Kg every 2 weeks7.5 mg/Kg every 3 weeks
AnalysisStage II and IIIStage III

 

Table 2. Ongoing Phase III Trials in Adjuvant Colon Cancer
 
RegimenStage IIStage II-IIIStage III
Abbreviations: BCTU = Birmingham Clinical Trials Unit; ECOG = Eastern Cooperative Oncology Group; FOxTROT = Fluoropyrimidine, Oxaliplatin, and Targeted Receptor Pre-Operative Therapy; NSABP = National Surgical Adjuvant Breast and Bowel Project.
Chemotherapy +/- BevacizumabECOG E5202NASBP C-08
AVANT
QUASAR 2
TOSCA (IDEA)		_
Chemotherapy +/- Cetuximab__PETACC8
NO147
Chemotherapy +/- Panitumumab_BCTU-FOxTROT_